● Recruiting

Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection

Condition: Non Small Cell Lung Cancer · Sponsor: University Health Network, Toronto

PhaseN/A

Planned participants360

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.

This description comes directly from the study's public registry record.

Talk to the study team

Mary Rabey · 416-946-4501 · mary.rabey@uhn.ca

Always discuss trial participation with your own doctor first.

Locations (3)

Michael Garron Hospital	Toronto, Ontario, Canada	Recruiting
St. Joseph's Health Centre	Toronto, Ontario, Canada	Recruiting
University Health Network	Toronto, Ontario, Canada	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05254782